| | Business Summary | | Genentech,
Inc.
is
a
biotechnology
company
that
uses
human
genetic
information
to
discover,
develop,
manufacture
and
market
human
pharmaceuticals
that
address
significant
unmet
medical
needs.
The
Company
manufactures
and
markets
nine
protein-based
pharmaceuticals
and
licenses
several
additional
products
to
other
companies.
In
general,
the
Company's
products
are
sold
to
distributors,
or
directly
to
hospital
pharmacies
or
medical
centers. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | DNA
is
a
biotechnology
company
that
uses
human
genetic
information
to
discover,
develop,
manufacture
and
market
human
pharmaceuticals
for
significant
unmet
medical
needs.
For
the
six
months
ended
6/30/01,
total
revenues
increased
31%
to
$1.06
billion.
Net
income
before
accounting
change
totaled
$71
million,
vs.
a
loss
of
$37.5
million.
Revenues
reflect
increased
sales
of
Rituxan
and
Herceptin.
Net
income
also
reflects
a
decrease
in
the
cost
of
sales. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Arthur Levinson, Ph.D., 51
Chairman,
Pres, CEO | $1.8M | $57M | Louis Lavigne, Jr., 52
CFO,
Exec. VP | 710K | 24M | Myrtle Potter, 42
COO,
Exec. VP -Commercial Operations | 1.6M | -- | Susan Desmond-Hellmann, M.D., 43
Exec.
VP, Devel. and Product Operations, CMO | 912K | 15M | Stephen Juelsgaard, 52
Sr.
VP, Gen. Counsel and Sec. | 561K | 21M | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/d/dna.gif)